1-20 of 1549
molecular targeted therapy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

Free
Andrew W. Roberts, Freda K. Stevenson
Journal: Blood
Blood (2021) 138 (13): 1089.
https://doi.org/10.1182/blood.2021012674
Published: 2021
Journal Articles

How I treat pediatric acute myeloid leukemia

Free
Jeffrey E. Rubnitz, Gertjan J. L. Kaspers
Journal: Blood
Blood (2021) 138 (12): 1009–1018.
https://doi.org/10.1182/blood.2021011694
Published: 2021
Journal Articles

CLL-IPI: valid in the era of oral inhibitors?

Free
Nadine Kutsch
Journal: Blood
Blood (2021) 138 (2): 106–107.
https://doi.org/10.1182/blood.2021011937
Published: 2021
Journal Articles

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 -mutated acute myeloid leukemia

Free
Wenbin Xiao, Alexander Chan, Michael R. Waarts, Tanmay Mishra, Ying Liu, Sheng F. Cai, Jinjuan Yao, Qi Gao, Robert L. Bowman, Richard P. Koche, Isabelle S. Csete, Nicole L. DelGaudio, Andriy Derkach, Jeeyeon Baik, Sophia Yanis, Christopher A. Famulare, Minal Patel, Maria E. Arcila, Maximilian Stahl, Raajit K. Rampal, Martin S. Tallman, Yanming Zhang, Ahmet Dogan, Aaron D. Goldberg, Mikhail Roshal, Ross L. Levine
Journal: Blood
Blood (2021) 137 (10): 1377–1391.
https://doi.org/10.1182/blood.2020007897
Published: 2021
Includes: Supplemental data
Journal Articles

How I treat warm autoimmune hemolytic anemia

Free
Wilma Barcellini, Bruno Fattizzo
Journal: Blood
Blood (2021) 137 (10): 1283–1294.
https://doi.org/10.1182/blood.2019003808
Published: 2021
Journal Articles

How I treat relapsed or refractory AML

Free
Susan DeWolf, Martin S. Tallman
Journal: Blood
Blood (2020) 136 (9): 1023–1032.
https://doi.org/10.1182/blood.2019001982
Published: 2020
Journal Articles

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Free
Johannes Schmoellerl, Inês Amorim Monteiro Barbosa, Thomas Eder, Tania Brandstoetter, Luisa Schmidt, Barbara Maurer, Selina Troester, Ha Thi Thanh Pham, Mohanty Sagarajit, Jessica Ebner, Gabriele Manhart, Ezgi Aslan, Stefan Terlecki-Zaniewicz, Christa Van der Veen, Gregor Hoermann, Nicolas Duployez, Arnaud Petit, Helene Lapillonne, Alexandre Puissant, Raphael Itzykson, Richard Moriggl, Michael Heuser, Roland Meisel, Peter Valent, Veronika Sexl, Johannes Zuber, Florian Grebien
Journal: Blood
Blood (2020) 136 (4): 387–400.
https://doi.org/10.1182/blood.2019003267
Published: 2020
Includes: Supplemental data
Journal Articles

Long-term follow-up of mTOR inhibition for Erdheim-Chester disease

Free
Clinical Trials & Observations
Francesco Pegoraro, Valerio Maniscalco, Francesco Peyronel, Pieter J. Westenend, Tadek R. Hendriksz, Rosa M. Roperto, Alessandro A. Palumbo, Elena Sieni, Paola Romagnani, Eric F. H. van Bommel, Augusto Vaglio
Journal: Blood
Blood (2020) 135 (22): 1994–1997.
https://doi.org/10.1182/blood.2019004478
Published: 2020
Includes: Supplemental data
Journal Articles

Management of ECD: the era of targeted therapies

Free
Oussama Abla
Journal: Blood
Blood (2020) 135 (22): 1919–1920.
https://doi.org/10.1182/blood.2020005803
Published: 2020
Journal Articles

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Free
Gaurav Goyal, Mark L. Heaney, Matthew Collin, Fleur Cohen-Aubart, Augusto Vaglio, Benjamin H. Durham, Oshrat Hershkovitz-Rokah, Michael Girschikofsky, Eric D. Jacobsen, Kazuhiro Toyama, Aaron M. Goodman, Paul Hendrie, Xin-xin Cao, Juvianee I. Estrada-Veras, Ofer Shpilberg, André Abdo, Mineo Kurokawa, Lorenzo Dagna, Kenneth L. McClain, Roei D. Mazor, Jennifer Picarsic, Filip Janku, Ronald S. Go, Julien Haroche, Eli L. Diamond
Journal: Blood
Blood (2020) 135 (22): 1929–1945.
https://doi.org/10.1182/blood.2019003507
Published: 2020
Journal Articles

Erdheim-Chester disease

Free
Julien Haroche, Fleur Cohen-Aubart, Zahir Amoura
Journal: Blood
Blood (2020) 135 (16): 1311–1318.
https://doi.org/10.1182/blood.2019002766
Published: 2020
Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Free
Clinical Trials & Observations
Jennifer A. Woyach
Journal: Blood
Blood (2019) 134 (21): 1796–1801.
https://doi.org/10.1182/blood.2019001321
Published: 2019
Journal Articles

The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia

Free
Samah Nassereddine, MD, Kimberley Doucette, MD MSc, Vanya Aggarwal, Richard Amdur, PhD, Imad A. Tabbara, MD, Catherine E. Lai, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2212.
https://doi.org/10.1182/blood-2019-124150
Published: 2019
Journal Articles

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Free
Valeria Visconte, PhD, Vera Adema, PhD, Anand D. Tiwari, PhD, Cassandra M Kerr, MS, Hassan Awada, Bartlomiej Przychodzen, Allison Noe, Rachel Toth, Christina Snider, Yvonne Parker, Yuriy Fedorov, Drew Adams, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Kevin R Kelly, MD PhD, Steffan T. Nawrocki, PhD, Jennifer S. Carew, PhD, Heesun J. Rogers, MD PhD, Daniel J. Lindner, Mikkael A. Sekeres, MD MS, James G Phillips, PhD, Jaroslaw P. Maciejewski, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 564.
https://doi.org/10.1182/blood-2019-129189
Published: 2019
Journal Articles

Tudor Domain-Focused CRISPR Dropout Screen Identifies SGF29 As a Novel Essential Gene in MLL -Rearranged Leukemias

Free
Anthony K. N. Chan, PhD, Christopher D. Delaney, Lu Yang, PhD, Wen-Han Chang, PhD, Kazuya Miyashita, PhD, Qiao Liu, MD, Sheela Pangeni Pokharel, MSc, Scott A. Armstrong, MD PhD, Chun-Wei David Chen, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 530.
https://doi.org/10.1182/blood-2019-131467
Published: 2019
Journal Articles

Targeting Bcl-2 Proteins in Myeloma

Free
Martine Amiot, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): SCI-11.
https://doi.org/10.1182/blood-2019-121103
Published: 2019
Journal Articles

Time to Second Treatment As a Proxy for Overall Survival in CLL/SLL: Identifying Risk Factors to Help Guide Treatment Selection

Free
Kurt S. Bantilan, MPH, Jacob D. Soumerai, MD, Lindsey E. Roeker, MD, Anthony R. Mato, MDMSCE, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4299.
https://doi.org/10.1182/blood-2019-130109
Published: 2019
Journal Articles

A Systematic Review of the Epidemiology and Economic Burden of Mantle Cell Lymphoma (MCL)

Free
Keri Keri Yang, Eleanor Lucas, BA, Beth Lesher, PharmD, Tony Caver, PhD, Boxiong Tang, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5831.
https://doi.org/10.1182/blood-2019-129677
Published: 2019
Journal Articles

Progression-Free Survival and Overall Survival Among a Patient Cohort of Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

Free
Martine Bagot, MD PhD, Timothy Illidge, MD PhD, Nicola Pimpinelli, MD, Mehul Dalal, PhD, Athanasios Zomas, Chalid Assaf, MD, Nathalie Waser, PhD, Zhouqin He, MSc, Tina Li, MPH, Robert Sambrook, MSc, Fabrizio Trinchese, Meredith Little, Nawal Bent-Ennakhil, Pablo L. Ortiz-Romero, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5879.
https://doi.org/10.1182/blood-2019-126246
Published: 2019
Journal Articles

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Free
Keri Keri Yang, Beth Lesher, PharmD, Eleanor Lucas, BA, Tony Caver, PhD, Boxiong Tang, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5881.
https://doi.org/10.1182/blood-2019-130896
Published: 2019